Structural basis for activation of the complement system by component C4 cleavage. 2012

Rune T Kidmose, and Nick S Laursen, and József Dobó, and Troels R Kjaer, and Sofia Sirotkina, and Laure Yatime, and Lars Sottrup-Jensen, and Steffen Thiel, and Péter Gál, and Gregers R Andersen
Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.

An essential aspect of innate immunity is recognition of molecular patterns on the surface of pathogens or altered self through the lectin and classical pathways, two of the three well-established activation pathways of the complement system. This recognition causes activation of the MASP-2 or the C1s serine proteases followed by cleavage of the protein C4. Here we present the crystal structures of the 203-kDa human C4 and the 245-kDa C4·MASP-2 substrate·enzyme complex. When C4 binds to MASP-2, substantial conformational changes in C4 are induced, and its scissile bond region becomes ordered and inserted into the protease catalytic site in a manner canonical to serine proteases. In MASP-2, an exosite located within the CCP domains recognizes the C4 C345C domain 60 Å from the scissile bond. Mutations in C4 and MASP-2 residues at the C345C-CCP interface inhibit the intermolecular interaction and C4 cleavage. The possible assembly of the huge in vivo enzyme-substrate complex consisting of glycan-bound mannan-binding lectin, MASP-2, and C4 is discussed. Our own and prior functional data suggest that C1s in the classical pathway of complement activated by, e.g., antigen-antibody complexes, also recognizes the C4 C345C domain through a CCP exosite. Our results provide a unified structural framework for understanding the early and essential step of C4 cleavage in the elimination of pathogens and altered self through two major pathways of complement activation.

UI MeSH Term Description Entries
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D008351 Mannans Polysaccharides consisting of mannose units. Mannan
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003181 Complement C4 A glycoprotein that is important in the activation of CLASSICAL COMPLEMENT PATHWAY. C4 is cleaved by the activated COMPLEMENT C1S into COMPLEMENT C4A and COMPLEMENT C4B. C4 Complement,C4 Complement Component,Complement 4,Complement C4, Precursor,Complement Component 4,Pro-C4,Pro-complement 4,C4, Complement,Complement Component, C4,Complement, C4,Component 4, Complement,Component, C4 Complement,Pro C4,Pro complement 4
D003461 Crystallography The branch of science that deals with the geometric description of crystals and their internal arrangement. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Crystallographies

Related Publications

Rune T Kidmose, and Nick S Laursen, and József Dobó, and Troels R Kjaer, and Sofia Sirotkina, and Laure Yatime, and Lars Sottrup-Jensen, and Steffen Thiel, and Péter Gál, and Gregers R Andersen
April 1998, Kidney international,
Rune T Kidmose, and Nick S Laursen, and József Dobó, and Troels R Kjaer, and Sofia Sirotkina, and Laure Yatime, and Lars Sottrup-Jensen, and Steffen Thiel, and Péter Gál, and Gregers R Andersen
April 1984, Cell,
Rune T Kidmose, and Nick S Laursen, and József Dobó, and Troels R Kjaer, and Sofia Sirotkina, and Laure Yatime, and Lars Sottrup-Jensen, and Steffen Thiel, and Péter Gál, and Gregers R Andersen
June 2015, Journal of immunology (Baltimore, Md. : 1950),
Rune T Kidmose, and Nick S Laursen, and József Dobó, and Troels R Kjaer, and Sofia Sirotkina, and Laure Yatime, and Lars Sottrup-Jensen, and Steffen Thiel, and Péter Gál, and Gregers R Andersen
October 1988, Journal of immunology (Baltimore, Md. : 1950),
Rune T Kidmose, and Nick S Laursen, and József Dobó, and Troels R Kjaer, and Sofia Sirotkina, and Laure Yatime, and Lars Sottrup-Jensen, and Steffen Thiel, and Péter Gál, and Gregers R Andersen
February 1970, Immunochemistry,
Rune T Kidmose, and Nick S Laursen, and József Dobó, and Troels R Kjaer, and Sofia Sirotkina, and Laure Yatime, and Lars Sottrup-Jensen, and Steffen Thiel, and Péter Gál, and Gregers R Andersen
November 1981, The Biochemical journal,
Rune T Kidmose, and Nick S Laursen, and József Dobó, and Troels R Kjaer, and Sofia Sirotkina, and Laure Yatime, and Lars Sottrup-Jensen, and Steffen Thiel, and Péter Gál, and Gregers R Andersen
August 1982, Nature,
Rune T Kidmose, and Nick S Laursen, and József Dobó, and Troels R Kjaer, and Sofia Sirotkina, and Laure Yatime, and Lars Sottrup-Jensen, and Steffen Thiel, and Péter Gál, and Gregers R Andersen
July 1979, FEBS letters,
Rune T Kidmose, and Nick S Laursen, and József Dobó, and Troels R Kjaer, and Sofia Sirotkina, and Laure Yatime, and Lars Sottrup-Jensen, and Steffen Thiel, and Péter Gál, and Gregers R Andersen
May 1997, Biological chemistry,
Rune T Kidmose, and Nick S Laursen, and József Dobó, and Troels R Kjaer, and Sofia Sirotkina, and Laure Yatime, and Lars Sottrup-Jensen, and Steffen Thiel, and Péter Gál, and Gregers R Andersen
November 1999, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!